→ Market Forecast 2023-2031:

The Anti-tuberculosis Therapeutics Market size was USD 2.1 billion in 2022.Covid-19's impacts have been unprecedented and staggering on a global scale, with the pandemic leading to positive demand shocks for the Anti-tuberculosis therapeutics market across all domains and regions. Between 2023 and 2031, the market is projected to grow at a CAGR of 5.3% from USD 1.9 billion in 2021 to USD 3.2 billion in 2031. The sudden rise in CAGR is attributed to this market growth returning to the pre-pandemic level once the pandemic is over.

The high prevalence of tuberculosis (TB) in developing nations, the rise of drug-resistant strains of the illness, and the rising usage of combination therapy are some of the factors propelling the market for anti-tuberculosis therapeutic products. Governments and international organisations are also funding TB-eradication programmes, which is anticipated to further fuel market expansion.

By drug class, including first-line, second-line, and additional medications, the market is divided. Isoniazid, rifampin, and pyrazinamide are some of the first-line medications that are frequently used to treat tuberculosis (TB). When first-line medications are ineffective or cannot be utilised, second-line medications, like fluoroquinolones and aminoglycosides, are prescribed.

A small number of significant companies, including Johnson & Johnson, Novartis AG, and Sanofi S.A., control the anti-tuberculosis pharmaceuticals industry. Pfizer Inc., Lupin Limited, and Otsuka Holdings Co., Ltd. are additional companies active in the market.

→ Scope of Anti-Tuberculosis Therapeutics Market Report:

A recent market research report added to repository of Intellectual Market Insights Research is an in-depth analysis of Global Anti-Tuberculosis Therapeutics Market. On the basis of historic growth analysis and current scenario of Anti-Tuberculosis Therapeutics market place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent tools that facilitate deeper understanding of multiple aspects of global Anti-Tuberculosis Therapeutics market. This further helps users with their developmental strategy.

This report examines all the key factors influencing growth of global Anti-Tuberculosis Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Anti-Tuberculosis Therapeutics market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, pricing strategies, innovation possibilities and much more.

The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

→ Market Drivers:

Rise in the prevalence of tuberculosis:

TB is a highly prevalent disease, and the number of cases worldwide has been increasing in recent years. According to the World Health Organization (WHO), there were an estimated 10 million TB cases worldwide in 2020, with 1.5 million deaths. The increasing incidence of TB is driving the demand for anti-tuberculosis therapeutics.

Increasing investment for healthcare infrastructure:

Governments and private organizations are investing heavily in healthcare infrastructure to improve the quality and availability of healthcare services. This investment includes the development of new hospitals, clinics, and research facilities, as well as the training of healthcare professionals. Such investment helps to increase the accessibility of anti-tuberculosis therapeutics to the population in need.

→ Market Trends:

Increasing use of digital technologies in TB treatment:

Digital technologies, such as mobile apps and telemedicine, are being used to improve TB diagnosis and treatment. For example, mobile apps can be used to monitor patient adherence to medication, while telemedicine can be used to provide remote consultations and support.

Rising demand for generic drugs:

Due to the high cost of branded drugs, there is growing demand for generic anti-tuberculosis drugs, particularly in developing countries where TB is more prevalent. This is driving the growth of the generic drugs segment in the anti-tuberculosis therapeutics market.

→Market Restraining Factors:

Adverse Side Effects of Anti-tuberculosis Drugs:

The drugs used to treat tuberculosis can have adverse side effects, such as nausea, vomiting, liver damage, hearing loss, and vision problems. The side effects can be severe and can reduce patient compliance with the treatment regimen. The risk of side effects can also increase with the use of more potent drugs, especially in patients with other health conditions. Therefore, the potential for adverse side effects limits the use of some of the most effective drugs, which can impact the effectiveness of tuberculosis treatment.

High Cost of MDR and XDR TB Drugs:

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis strains require more potent and specialized drugs for treatment. These drugs are typically more expensive than standard tuberculosis drugs, making them less accessible to patients in low- and middle-income countries where the disease is more prevalent. Moreover, the high cost of these drugs can create significant financial burdens for patients and healthcare systems, limiting their availability and affordability.

→ Key Players Analysis:

The market for anti-tuberculosis therapeutics is extremely consolidated, with only a handful of companies controlling a sizable portion of the industry. Smaller to mid-sized businesses are anticipated to enter the market in the near future as a result of the healthcare sector's increased focus on the creation of novel pharmaceuticals and the expanding expenditure in R&D.

The biggest market share is currently held by businesses like Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson.

→ List of Companies Profiled:

The following is a list of companies that have been profiled in the Anti-tuberculosis therapeutics market report:

• Macleods Pharmaceuticals Ltd
• Otsuka Pharmaceutical Co. Ltd
• Johnson and Johnson
• Sequella, Inc.
• Lupin Limited
• Healthy Life Pharma Private Limited
• Mylan N.V.
• Sun Pharmaceutical Industries
• Novartis AG
• Pfizer Inc.
• Sanofi
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Cipla Inc.
• Lannett

→ Key Industry Developments:

• In March 2022: Johnson & Johnson India launched a youth-focused, digital initiative, Be the Change For TB, a joint initiative with the Union Ministry of Health’s Central TB Division and the United States Agency for International Development, as part of its corporate pledge against tuberculosis.
• In September 2021: TB Alliance, a non-profit drug developer, granted a non-exclusive license to Lupin for developing the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Under the license, Lupin commercializes the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.

Anti-Tuberculosis Therapeutics Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2022-2031 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.

→ Segmentation Analysis:

By Disease Type

Active TB: This segment includes drugs and other treatments used to treat active TB, which is characterized by symptoms such as coughing, fever, and weight loss. Active TB is caused by the bacterium Mycobacterium tuberculosis and is spread through the air when an infected person coughs or sneezes.

Latent TB: This segment includes drugs and other treatments used to treat latent TB, which is a non-active form of TB. People with latent TB do not have any symptoms and are not infectious, but they have been infected with the bacterium and may develop active TB in the future. Treatments for latent TB are used to prevent the development of active TB.

Others: This segment includes drugs and other treatments used to treat other forms of TB, such as extrapulmonary TB, which affects parts of the body other than the lungs. Extrapulmonary TB can affect the bones, joints, lymph nodes, and other organs.

By Treatment Type

First-line drugs: This segment includes the most commonly used drugs for the treatment of TB, such as isoniazid, rifampin, and pyrazinamide. These drugs are highly effective in treating TB and are often used in combination with each other. First-line drugs are typically used to treat drug-susceptible TB.

Second-line drugs: This segment includes drugs used to treat drug-resistant TB, which occurs when the bacteria that cause TB become resistant to first-line drugs. Second-line drugs are typically used in combination with each other to increase their effectiveness. Examples of second-line drugs include fluoroquinolones and aminoglycosides.

Others: This segment includes other types of treatments used to treat TB, such as immunotherapy and surgical interventions. Immunotherapy involves the use of drugs or other substances to stimulate the immune system to fight the TB bacteria. Surgical interventions may be used in some cases to remove infected tissue or to drain abscesses.

By Diagnosis

Blood tests: This segment includes tests that measure specific antibodies or antigens in the blood that indicate the presence of TB. Blood tests are non-invasive and can provide quick results, but they are less accurate than other diagnostic methods.

Imaging tests: This segment includes tests such as chest X-rays and computed tomography (CT) scans that are used to visualize the lungs and other organs for signs of TB infection. Imaging tests are useful for detecting TB-related changes in the lungs, but they are not definitive and may require further testing.

Sputum tests: This segment includes tests that analyze sputum, or mucus coughed up from the lungs, for the presence of TB bacteria. Sputum tests are a common method for diagnosing TB and can be done using smear microscopy or culture-based methods. Smear microscopy is a rapid and inexpensive method, while culture-based methods are more sensitive and can detect low levels of TB bacteria.

Others: This segment includes other diagnostic methods such as nucleic acid amplification tests (NAATs), which detect TB DNA or RNA in sputum or other samples, and skin tests such as the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs), which detect the presence of TB antigens in the skin or blood.

By Route of Administration

Oral: This segment includes drugs that are taken by mouth, such as tablets or capsules. Oral drugs are the most commonly used route of administration for TB treatment, as they are convenient and easy to administer.

Parenteral: This segment includes drugs that are delivered by injection, either into a muscle or into a vein. Parenteral drugs may be used in cases where oral drugs are not effective or in patients who are unable to take oral medications.

Others: This segment includes other methods of drug delivery, such as inhalation or topical application. Inhalation is a method used for drugs such as Bed aquiline, while topical administration is used for drugs like Capreomycin.

By Dosage Form

Tablets: This segment includes drugs that are formulated into solid dosage forms, such as tablets or pills. Tablets are a common dosage form for oral drugs, and they are available in various strengths and formulations.

Capsules: This segment includes drugs that are formulated into capsules, which are also a solid dosage form. Capsules may be used to deliver drugs that are not suitable for tablet formulation or to improve drug absorption.

Injections: This segment includes drugs that are formulated for injection, either into a muscle or into a vein. Injectables may be used in cases where oral medications are not effective, or when immediate drug action is required.

Others: This segment includes other forms of drug delivery, such as liquids, powders, and inhalers. Liquids may be used for patients who are unable to swallow tablets or capsules, while inhalers may be used for patients with TB-related lung disease.

By End-User

Hospitals: This segment includes hospitals that provide inpatient care for patients with TB, such as those with severe or complicated cases of the disease. Hospitals may also provide outpatient care for TB patients who require regular monitoring and follow-up.

Specialty clinics: This segment includes clinics that specialize in the treatment of TB and other respiratory diseases. Specialty clinics may offer diagnostic testing, treatment, and follow-up care for TB patients.

Homecare: This segment includes patients who receive TB treatment at home, either through self-administration or with the help of a caregiver. Homecare may be used for patients with mild to moderate TB who do not require hospitalization.

Others: This segment includes other healthcare providers or facilities, such as community health centers, public health departments, and non-governmental organizations (NGOs).

By Distribution Channel

Hospital pharmacy: This segment includes drugs that are distributed through hospital pharmacies, which are located within hospitals and provide medications for inpatient and outpatient care. Hospital pharmacies may also provide medication counseling and monitoring services.

Retail pharmacy: This segment includes drugs that are distributed through retail pharmacies, which are located in the community and provide medications for outpatients. Retail pharmacies may also provide medication counseling and monitoring services.

Online pharmacy: This segment includes drugs that are distributed through online pharmacies, which allow patients to order and receive medications through the internet. Online pharmacies may provide convenient access to TB drugs for patients who live in remote areas or have difficulty accessing traditional healthcare facilities.

Others: This segment includes other methods of drug delivery, such as specialty pharmacies, mail-order pharmacies, and drug wholesalers

The report also helps in understanding Global Anti-Tuberculosis Therapeutics Market dynamics, structure by analyzing the market segments, and project the Global Anti-Tuberculosis Therapeutics Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-Tuberculosis Therapeutics Market make the report investor’s guide.

→ Report Coverage:

The report will cover the qualitative and quantitative data on the Anti-tuberculosis therapeutics market. The qualitative data includes latest trends, market player’s analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

→ Report Scope and Segmentations:

→ Regional Snapshots:

Here are some regional snapshots of the Anti-tuberculosis therapeutics market:

North America: The North American market for anti-tuberculosis therapeutics is expected to grow steadily due to the increasing prevalence of TB in the region. The market is dominated by the US, which has a strong healthcare infrastructure and a high demand for TB drugs. The market is also supported by the presence of major pharmaceutical companies in the region.

Europe: The European market for anti-tuberculosis therapeutics is expected to grow at a moderate pace due to the declining incidence of TB in the region. The market is dominated by Western European countries, which have well-established healthcare systems and high levels of drug reimbursement. The market is also driven by the increasing demand for new TB drugs and the presence of key players in the region.

Asia-Pacific: The Asia-Pacific market for anti-tuberculosis therapeutics is expected to grow rapidly due to the high burden of TB in the region. The market is dominated by India and China, which together account for a significant share of the global TB burden. The market is also driven by the increasing availability of generic TB drugs, the rising demand for new TB drugs, and the efforts of governments and NGOs to improve TB diagnosis and treatment.

Latin America: The Latin American market for anti-tuberculosis therapeutics is expected to grow at a moderate pace due to the declining incidence of TB in the region. The market is dominated by Brazil and Mexico, which have well-established healthcare systems and a high demand for TB drugs. The market is also driven by the increasing availability of generic TB drugs and the efforts of governments and NGOs to improve TB diagnosis and treatment.

Middle East & Africa: The Middle East & Africa market for anti-tuberculosis therapeutics is expected to grow at a moderate pace due to the high burden of TB in the region. The market is dominated by South Africa, which has the highest incidence of TB in the region. The market is also driven by the increasing availability of generic TB drugs and the efforts of governments and NGOs to improve TB diagnosis and treatment.

→ Regional Analysis:

North America accounted for the highest xx% market share in terms of revenue in the Anti-Tuberculosis Therapeutics market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Anti-Tuberculosis Therapeutics. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Anti-Tuberculosis Therapeutics companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Anti-Tuberculosis Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Anti-Tuberculosis Therapeutics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

→ Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

→ Key Questions:

• How much the global Anti-Tuberculosis Therapeutics Market valued?
• Which region has the largest share in 2023 for the global Anti-Tuberculosis Therapeutics Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

→ Research Scope of Anti-Tuberculosis Therapeutics Market:

• Historic year: 2018- 2021
• Base year: 2022
• Forecast: 2023 to 2031
• Representation of Market revenue in USD Million

Anti-Tuberculosis Therapeutics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: